Ginkgo Bioworks Holdings, Inc.
DNA
$10.76
-$0.43-3.84%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.75% | 27.34% | 26.16% | 60.65% | -30.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.75% | 27.34% | 26.16% | 60.65% | -30.24% |
| Cost of Revenue | 8.02% | 30.92% | 45.55% | 73.38% | -24.18% |
| Gross Profit | -18.13% | 26.20% | 21.61% | 58.83% | -31.99% |
| SG&A Expenses | -34.71% | -30.22% | -20.12% | -36.25% | -26.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 312.85% | -- | -- | -- |
| Total Operating Expenses | -47.97% | -36.29% | -26.89% | -42.47% | -14.06% |
| Operating Income | 60.85% | 50.01% | 38.86% | 72.52% | 6.34% |
| Income Before Tax | 72.08% | 45.22% | 49.10% | 81.26% | -25.25% |
| Income Tax Expenses | -248.95% | 183.87% | -64.14% | -1,604.55% | 183.58% |
| Earnings from Continuing Operations | 72.24% | 45.18% | 49.20% | 81.38% | -25.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.24% | 45.18% | 49.20% | 81.38% | -25.31% |
| EBIT | 60.85% | 50.01% | 38.86% | 72.52% | 6.34% |
| EBITDA | 67.25% | 55.48% | 44.39% | 79.25% | 6.87% |
| EPS Basic | 74.00% | 49.35% | 53.33% | 82.62% | -17.91% |
| Normalized Basic EPS | 63.46% | 53.68% | 41.68% | 78.14% | 14.00% |
| EPS Diluted | 74.00% | 49.38% | 53.37% | 82.61% | -17.53% |
| Normalized Diluted EPS | 63.46% | 53.66% | 41.64% | 78.14% | 14.01% |
| Average Basic Shares Outstanding | 6.79% | 8.24% | 8.84% | 7.12% | 6.28% |
| Average Diluted Shares Outstanding | 6.78% | 8.19% | 8.78% | 7.13% | 6.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |